{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-23-000720","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.813293+00:00","generated_at":"2026-06-19T02:43:06.137223+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ReWalk Q4 revenue $2.2M (+75% YoY); full-year net loss $19.6M; cash $67.9M no debt","bullets":["Q4 2022 revenue $2.2M, up 75% from $1.2M in Q4 2021; full-year revenue $5.5M vs $6.0M in 2021.","Q4 net loss $5.3M ($3.9M in Q4 2021); full-year net loss $19.6M ($12.7M in 2021).","Cash and equivalents $67.9M as of Dec 31, 2022, with no debt.","Submitted first exoskeleton claim for Medicare coverage via MACs in Q4; preparing for expanded patient access.","Repurchased $3.3M of ordinary shares since Q3 2022; record quarterly MyoCycle sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-23-000720","json":"https://secwatch.observer/filing/0001178913-23-000720.json","markdown":"https://secwatch.observer/filing/0001178913-23-000720.md","text":"https://secwatch.observer/filing/0001178913-23-000720.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891323000720/0001178913-23-000720-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891323000720/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:43:06.137223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"285b3e0b25006c6c5c786c119b332f96d14e39a1","claim":"Lifeward Ltd. reported the fourth quarter of 2022 results: revenue $2.2 million, net income $5.3 million net loss.","evidence_excerpt":"Revenue was $2.2 million in the fourth quarter of 2022, an increase of 75% as compared to $1.2 million during the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891323000720/0001178913-23-000720-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$2.2 million"},{"label":"Net income","value":"$5.3 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7cd93fdd80e8fabf58adf88a7f8c0e16d3de6d01","claim":"Lifeward Ltd. reported the fiscal year ended December 31, 2022 results: revenue $5.5 million, net income $19.6 million net loss.","evidence_excerpt":"Annual revenue was $5.5 million in 2022 compared to $6.0 million in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891323000720/0001178913-23-000720-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$5.5 million"},{"label":"Net income","value":"$19.6 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}